Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide - Wikidata - awgldk - TriplyDB

Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide

Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide

http://www.wikidata.org/entity/Q28277241

about

Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia Arsenic trioxide induces apoptosis in the THP1 cell line by downregulating EVI-1 Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells.Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide.Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression.Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide Arsenic suppresses cell survival via Pirh2-mediated proteasomal degradation of ΔNp63 protein.Biological responses to arsenic compounds Ecotropic viral integration site 1, stem cell self-renewal and leukemogenesis.Enhanced sensitivity to hydrogen peroxide-induced apoptosis in Evi1 transformed Rat1 fibroblasts due to repression of carbonic anhydrase III.Direct binding of arsenic trioxide to AMPK and generation of inhibitory effects on acute myeloid leukemia precursors.Ecotropic viral integration site 1, a novel oncogene in prostate cancer.Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient.EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia.Response to lenalidomide of a patient with t(2;3)(p23;q29) and JAK2 non-mutated refractory anemia with ring sideroblasts and thrombocytosis.miRNA-22 is a Novel Mediator of Vascular Smooth Muscle Cell Phenotypic Modulation and Neointima Formation.

P2860

Q24623800-2C7A7081-A154-4965-9F9F-BDC8BD56DEBD Q24631549-AB305E85-0A3A-4832-8D77-A12A454F2321 Q28387697-B4301C47-EA0E-4015-9B6C-A86461B589C8 Q33769741-6A78E166-2036-4D79-9AA6-4D02BA691A32 Q34101387-5A400D9B-23BA-41CC-964F-82545B44C15D Q34144553-80607B21-32FF-4836-ABBA-D4AC796BB056 Q34978872-873C588F-4ED2-491E-8B77-6C96E79ABB33 Q36300433-C6987E8B-EA99-4EC5-8E0C-C346B14BAAD6 Q36352545-66912851-E1A6-48CB-B506-F4EDACCE5B94 Q36579412-15D44DFF-9848-49BC-8B73-E037C273F702 Q37442397-49E20FC1-89DF-4876-ADE9-1C5B0F2E0FA5 Q38001764-6997EA97-37EB-4BBA-A090-8C8859971C54 Q38347948-2EC6BD4D-488B-4419-A487-7E56B5041302 Q38945222-37FDE3DC-8216-41C2-8C33-03B2327DA122 Q39401617-D521DC33-8669-454B-BF95-0842C4B2A63F Q41875544-5C9B7686-E643-453E-8091-137DDE83F3B6 Q43486412-6C94CD48-1197-43D5-9653-74A2A3C3D155 Q44527886-457B14FF-75C0-4276-A1E0-7A542C0BBB97 Q47287722-876218A6-7902-4534-9FC8-E9B2FD51BC05

P2860

Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide

http://www.wikidata.org/entity/Q28277241

description

2006 nî lūn-bûn

@nan

2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide

@ast

Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide

@en

Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide

@nl

type

label

Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide

@ast

Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide

@en

Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide

@nl

prefLabel

Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide

@ast

Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide

@en

Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide

@nl

P1433

Q28277241-1EB8D9C6-90C5-4F40-95D0-D6C47BC681F2

P1476

Q28277241-E337A9F9-F282-482D-B118-F3D382224287

P2093

Q28277241-0B76638C-3B26-471C-874E-EF797890E302

Q28277241-13B9FF02-C63D-4765-947C-8FDCC981B3EB

Q28277241-9E99771B-D985-4620-8968-0E233DD399BA

Q28277241-ACC29F09-D197-4EF7-A51E-ACC4A236600D

P304

Q28277241-9E540F42-C5BF-42EA-8D69-0F15620849D7

P31

Q28277241-E62C5190-0722-4DC5-AEF5-11C753E0726C

P356

Q28277241-60AD6050-B2A3-4AF0-99AE-BBF880C7F832

P407

Q28277241-E1F9D92A-A278-4358-B9AC-EA5147FA129E

P433

Q28277241-CF74CF78-F32C-4691-B83F-6A33BAF4F715

P478

Q28277241-8A382FCB-D322-411C-9161-BA9DCEE1D9A2

P50

Q28277241-DA660665-40FF-4382-B95E-4F8C8BFEB74D

P577

Q28277241-C5BC1824-71E7-44B3-8427-26F16B70918A

P5875

Q28277241-53F18749-8872-450D-A3B3-D9C8DA58E94D

P698

Q28277241-ECCB6EF3-2FB5-42CE-AC38-403DBF54F58D

P356

0008-5472.CAN-06-1774

P1433

Cancer Research

P1476

Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide

@en

P2093

Agnieszka Blusztajn

http://www.w3.org/2001/XMLSchema#string

Candia Kenific

http://www.w3.org/2001/XMLSchema#string

David Shackelford

http://www.w3.org/2001/XMLSchema#string

Ruibao Ren

http://www.w3.org/2001/XMLSchema#string

P304

11360-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-06-1774

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6653005

http://www.w3.org/2001/XMLSchema#string

P698

17145882

http://www.w3.org/2001/XMLSchema#string